Strong CD4(+) T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination

BACKGROUND: NVX-CoV2373 is an efficacious coronavirus disease 2019 (COVID-19) vaccine comprising full-length recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (rS) glycoprotein and Matrix-M adjuvant. Phase 2 of a randomized, placebo-controlled, phase 1/2 trial in healthy...

Descripción completa

Detalles Bibliográficos
Autores principales: Fries, Louis, Formica, Neil, Mallory, Raburn M, Zhou, Haixia, Plested, Joyce S, Kalkeri, Raj, Moldovan, Ioana, Patel, Nita, Albert, Gary, Robinson, Michelle, Cho, Iksung, Chau, Gordon, Dubovsky, Filip, Glenn, Gregory M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503953/
https://www.ncbi.nlm.nih.gov/pubmed/37210741
http://dx.doi.org/10.1093/infdis/jiad163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503953/
https://www.ncbi.nlm.nih.gov/pubmed/37210741
http://dx.doi.org/10.1093/infdis/jiad163

Ejemplares similares